Status:
RECRUITING
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Lead Sponsor:
Merus N.V.
Conditions:
Head and Neck Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head an...
Detailed Description
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ HNSCC. ...
Eligibility Criteria
Inclusion
- Signed ICF before initiation of any study procedures
- Age ≥ 18 years at signing of ICF
- Histologically confirmed HNSCC with evidence of metastatic or locally recurrent disease not amenable to local therapy with curative intent.
- The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
- HNSCC patients eligible to receive pembrolizumab as 1L monotherapy with tumors expressing PD-L1, CPS ≥1.
- HNSCC patients should not have had previous systemic therapy administered in the incurable recurrent or metastatic setting
- A new tumor biopsy, unless the patient has an available archival tumor sample with sufficient material
- Measurable disease per Investigator assessment as defined by RECIST v1.1 by radiologic methods
- ECOG Performance Status (PS) of 0-1
- Life expectancy ≥ 12 weeks, as per investigator assessment.
- Left ventricular ejection fraction (LVEF) ≥50% or ≥ institutional normal limit, whichever is higher, by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
- Adequate organ function as defined per protocol.
- HIV-positive patients are eligible only if the cluster of differentiation 4 (CD4+) count is ≥ 300/µl, viral load is undetectable, and the patient is currently receiving highly active antiretroviral therapy
Exclusion
- Central nervous system metastases that are untreated or already treated but symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 21 days prior to randomization
- Known leptomeningeal involvement
- Any systemic anticancer therapy or investigational drug within 4 weeks or 5 half-lives, whichever is shorter, before randomization
- Requirement for immunosuppressive medication
- Major surgery or radiotherapy within 3 weeks of randomization
- Clinically significant toxicities related to prior anticancer therapies that have not returned to ≤ Grade 1 or baseline except for Grade ≤2- myalgia, neuropathy, alopecia, and any prior therapy related endocrinopathies
- History of hypersensitivity reaction to any of the excipients of petosemtomab or pembrolizumab.
- Unstable angina; history of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment; or history of myocardial infarction within 6 months prior to randomization
- History of prior malignancies within the last 5 years, with the exception of excised local cancer
- Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy
- Current serious illness or medical conditions including, but not limited to, uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders
- Patients with known infectious diseases as per protocol.
- Pregnant or breastfeeding patients.
- The patient has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy of prednisone \>10 mg/day or equivalent, or any other form of immunosuppressive therapy
- The patient has an active autoimmune disease that has required systemic immune suppressive treatment in the past 2 years; replacement therapy is not considered immune suppressive treatment
- The patient has had an allogeneic tissue/solid organ transplant.
- Patient has a primary tumor site of nasopharynx, or sinonasal carcinoma (any histology)
- Other protocol defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
September 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2030
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06525220
Start Date
September 25 2024
End Date
July 1 2030
Last Update
December 19 2025
Active Locations (175)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 164
Mobile, Alabama, United States, 36607
2
Site 36
La Jolla, California, United States, 92037
3
Site 27
Los Angeles, California, United States, 90033
4
Site 16
Palo Alto, California, United States, 94304